One of the benefits to raking in $6.7 billion in free cash flow is that you can splurge a little if you don't feel like developing something in-house.
Such is the case with Merck
The drugmaker is paying $130 million for Insmed's
Merck and Eli Lilly
The purchase by Merck helps it catch up a little, and it should put the company in a good position to be able to submit a marketing application in the U.S., once the FDA starts accepting them. When it comes to revenue growth, Merck can certainly use all the help it can get.
Let us know what you think in Motley Fool CAPS. Make an outperform or underperform call on these companies or post a pitch about whether you think companies will benefit from follow-on biologics. It's free. It's fun. And, it's Foolish.